ASX Announcement
- Supporting the future of stroke care: Hydrix engaged to support development of a next-generation AI enabled robotic stroke treatment platform.
- Combining AI, robotics and ultrasound: Quantanosis is pursuing a novel non-invasive approach to the treatment of acute stroke.
- Progressing development activities: The engagement has been extended to support further investigation of therapeutic ultrasound delivery and system performance.
- Building strategic capability: The project expands Hydrix’s experience across advanced medical robotics and AI-enabled healthcare technologies.
Hydrix Limited (ASX: HYD) (Hydrix) is pleased to announce that it has been engaged by US-based medical technology company Quantanosis Ai Inc. (Quantanosis) to support the preliminary stages of the development program for the company’s next-generation robotic stroke treatment platform.
Stroke remains one of the leading causes of death and long-term disability worldwide, with patient outcomes heavily dependent on rapid access to treatment. Despite significant advances in stroke care, many patients remain unable to receive timely intervention due to the specialised infrastructure, equipment and clinical expertise required to deliver current therapies.
Quantanosis is developing a novel non-invasive platform that combines advanced robotics, artificial intelligence and Histotripsy ultrasound with the goal of rapidly targeting and treating stroke-causing blood clots. The company describes its mission as “democratising stroke treatment” by expanding access to advanced stroke care beyond specialist intervention centres.
The technology seeks to address one of the most significant challenges in modern healthcare: delivering life saving stroke treatment quickly enough to minimise permanent neurological injury. By combining robotic automation with therapeutic ultrasound technologies, Quantanosis is pursuing an approach that has the potential to fundamentally change how acute stroke treatment is delivered in the future.
Following encouraging initial results from simulation and modelling activities, Quantanosis has extended Hydrix’s engagement to support further investigation of therapeutic ultrasound delivery and system performance as development of the platform progresses.
The engagement further expands Hydrix’s experience in the development of advanced robotic, AI-enabled and mission-critical systems. Through programs spanning healthcare, industrial and defence sectors, Hydrix continues to apply its multidisciplinary capabilities in software, electronics, sensing, automation and complex system integration to support the development of next-generation technologies.
Hydrix Chairman and CEO Gavin Coote said:
“Hydrix has a long history of developing complex mission-critical systems that combine advanced software, electronics, sensing, automation and intelligent control technologies. These multidisciplinary capabilities are increasingly important across next-generation healthcare, industrial and defence applications.
Quantanosis is pursuing a highly innovative approach to one of healthcare’s most significant unmet needs, and we are pleased to continue supporting the program’s development.
What excites us most is not only the technology itself, but the potential impact. If successful, platforms such as Quantanosis could help expand access to advanced stroke treatment and improve outcomes for patients who may not otherwise receive timely intervention.”
Quantanosis Co-Founder and Chief Executive Officer Dr Ameer Hassan said:
“Our vision is to fundamentally change how acute stroke treatment is delivered by combining robotics, artificial intelligence and histotripsy into a non-invasive treatment platform.
Hydrix is playing an important role in helping us develop that vision, contributing specialist engineering expertise and working closely with our team as we advance the technology. We are pleased to continue building on the strong collaboration established to date.”
Hydrix and Quantanosis will continue to collaborate as development of the platform progresses toward future technical and clinical milestones.
–ENDS-
This announcement is authorised for release by the Board of Directors of Hydrix Limited.
For more information, please contact:
| Hydrix Enquiries: | Alan Morris – Marketing Director |
| alan.morris@hydrixltd.com | |
| +61 3 9550 8100 | |
| Media Enquiries: | Rod North – Managing Director, Bourse Communications |
| rod@boursecommunications.com.au | |
| +61 3 9510 8309 | |
| Investor Enquiries: | Niv Dagan – Executive Director, Peak Asset Management |
| niv.dagan@peak assetmanagement.com.au | |
| M 0402 912 198 |
About Hydrix Limited
Hydrix Limited’s (ASX: HYD) mission is to harness the full potential of its innovation capability to deliver high impact technologies that empower lives. Hydrix leverages its powerful product innovation capability across three business segments: Services: design, engineer and deliver world first products and innovation across medtech and defence markets; Ventures: invest in high potential medtech clients; and Medical: distribute disruptive cardiovascular products. www.hydrixltd.com.
About Quantanosis Ai
Quantanosis is developing a new generation of medical instruments and devices for rapid stroke detection and treatment. Its non-invasive, operator-independent and portable technologies combine advanced artificial intelligence with focused ultrasound-based therapies to enable rapid diagnosis and treatment initiation. Quantanosis is focused on expanding access to timely stroke care through technologies designed to deliver critical care anywhere it is needed. www.quantanosis.ai